Navigation Links
Increase in drug development for killer diseases is not enough

A recent report shows that drug development for killer diseases such as HIV/AIDS, TB, Malaria, Chagas and Sleeping Sickness has increased in recent years. This is despite the fact that these diseases mainly affect the poor in developing countries and development of treatments is inhibitive due to lack of economic demand. Researchers argue that the rate of development of drugs (and of some vaccines and diagnostics) would increase if more incentives were created using patent rights and providing guarantees to purchase drugs for the poor as they are developed.

The report (The New Landscape of Neglected Disease Drug Development) by Mary Moran and colleagues at the Pharmaceutical Research and Development Policy Group, The George Institute, argues that drugs for neglected diseases are increasingly being developed partly due to the use of public-private partnership (PPPs) mechanisms that spread the financial and organisational risk of product development. Anne-Laure Ropars, from the George Institute will be discussing the rise of drug development for neglected diseases and the role of PPPs at a major international conference, organised by the ESRC Innogen Centre to be held in London on 5-6 September 2006.

Steven Matlin, Executive Director of the Global Forum for Health Research, also speaking at the conference, does not believe that the increases in development of health products for neglected diseases (drugs, vaccines and diagnostics) is simply due to the rise of PPPs. Matlin also stresses the rise of a group of 'innovating developing countries' (IDCs) including Brazil, China, India and South Africa. He argues that these countries have "growing national capacity for high-quality manufacturing to convert the inventions into health products for both domestic and international markets."

Matlin does acknowledge the challenges faced by both PPPs and IDCs in developing health products for neglected diseases. The third speaker in this conference sessi on, Robert Eiss, Executive Director of the Centre for the Management of Intellectual Property in Health Research, tackles these challenges in more depth. Eiss believes that correct market incentives and, in particular, appropriate intellectual property management are lacking. Eiss states that there is a "need to develop and promote forms of intellectual property management and technology transfer practice that help ensure access for the poor through the strategic use of such tools as price tiering and market segmentation, and the engagement of R&D and manufacturing capacities in countries where the targeted disease is endemic."


'"/>

Source:Economic & Social Research Council


Related biology news :

1. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
2. Increased risk of osteoporosis associated with gene that one in five people have
3. WHO Warns Of Increased Risk Of Vector-borne Diseases In Tsunami-affected Areas
4. Morphine for Chest Pain Increases Death Risk
5. Sea Ice May Be on Increase in the Antarctic
6. Use of Antibiotics for Acne May Increase Risk of Common Illness
7. Increased sensitivity to nerve signals keeps diabetes at bay
8. Increase in carbon dioxide emissions accelerating
9. A much-needed shot in the arm for HIV vaccine development
10. Clam embryo study shows pollutant mixture adversely affects nerve cell development
11. Zebrafish may hold key to understanding human nerve cell development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification ... Used combined in one project, multi-biometric solutions provide a ... ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today ... to uncover insights to support its reporting, help direct future ... UK,s leading youth charity will be using Brandwatch Analytics social listening ... better understanding of the topics and issues that are a priority ... ...
(Date:3/2/2017)... 2, 2017 Summary This report ... Merck KGaA and its partnering interests and activities since ... Description The Partnering Deals and Alliance since 2010 ... of one of the world,s leading life sciences companies. ... purchase to ensure inclusion of the most up to ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... March 29, 2017 Patients are the most ... CSL Behring awards Local Empowerment for Advocacy Development (LEAD) ... groups. These groups tackle complex legislative and public policy ... Hill and in statehouses across the U.S. ... was awarded to New England Hemophilia Association (NEHA), Neuropathy ...
(Date:3/29/2017)... COLORADO SPRINGS, CO , March 29, 2017 /PRNewswire/ - Last year,s ... who support kratom are not the only efforts active to generate ... that substitute opiate based pharmaceutical drugs in the healthcare market place. ... Earlier this ... U.S. based developer and distributor of pharmaceutical and nutritional products, announced ...
(Date:3/29/2017)... ... March 29, 2017 , ... ComplianceOnline, the leading governance, ... announced its 3rd Annual Medical Device Summit 2017 venue and speaker lineup. The Summit ... Hotel, in Boston, MA. , The Omni Parker House Hotel, which is located at ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... cell-based assays, disperses a quarterly travel award to noteworthy scientists who will be ... announced that its new round of awards are being given to two postdoctoral ...
Breaking Biology Technology: